Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs Pfizer Inc — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $36.5 (market cap $2.98B), while Pfizer Inc trades at $27.69 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 53.2× MicroSectors FANG and Innovation 3X Leveraged ETN's market cap, and Pfizer Inc pays a 6.18% dividend while MicroSectors FANG and Innovation 3X Leveraged ETN pays none. Which is the better fit depends on your goals — on Pluang, investors hold MicroSectors FANG and Innovation 3X Leveraged ETN for 19 Days and Pfizer Inc for 158 Days on average.
| FNGU | PFE | |
|---|---|---|
Market Cap | $2.98B | $158.56B |
Volume | 4,682,352 | 44,138,282 |
Sector | Leveraged / Inverse | Health |
52-Week High | $37.20 | $29.02 |
52-Week Low | $13.73 | $23.67 |
Typical Hold Time | 19 Days | 158 Days |
Enterprise Value | — | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3X leveraged ETN tracking major tech stocks, trades at $37.20 with a 1.92% daily gain. Technical indicators show strong bullish momentum with moving averages unanimously positive, though RSI levels suggest potential overbought conditions. The ETN faces significant volatility risks given its leveraged structure and concentration in top AI and tech names.
While the bullish technical setup and exposure to market-leading tech stocks present short-term upside potential, FNGU carries substantial risk from its triple leverage and historical volatility. Investors should be cautious of rapid drawdowns similar to the 87% decline experienced during previous tech sector corrections.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
